Total Payments
$1,071
2020 Payments
$58.16
Companies
17
Transactions
48
Medicare Patients
2,919
Medicare Billing
$637,840
Payment Breakdown by Category
Food & Beverage$971.67 (90.8%)
Education$98.98 (9.2%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $971.67 | 46 | 90.8% |
| Education | $98.98 | 2 | 9.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Astellas Pharma US Inc | $207.12 | 5 | $0 (2018) |
| Merck Sharp & Dohme Corporation | $156.35 | 10 | $0 (2019) |
| Insmed, Inc. | $138.62 | 3 | $0 (2020) |
| ViiV Healthcare Company | $129.58 | 6 | $0 (2018) |
| Theravance Biopharma, Inc. | $104.38 | 6 | $0 (2018) |
| Gilead Sciences, Inc. | $63.26 | 3 | $0 (2018) |
| Allergan, Inc. | $38.42 | 2 | $0 (2020) |
| Theratechnologies Inc. | $38.14 | 2 | $0 (2018) |
| Janssen Biotech, Inc. | $34.96 | 2 | $0 (2018) |
| E.R. Squibb & Sons, L.L.C. | $32.98 | 2 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2020 | $58.16 | 3 | Insmed, Inc. ($34.00) |
| 2019 | $228.11 | 8 | Insmed, Inc. ($104.62) |
| 2018 | $335.13 | 15 | Astellas Pharma US Inc ($120.41) |
| 2017 | $449.25 | 22 | ViiV Healthcare Company ($111.76) |
All Payment Transactions
48 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 07/07/2020 | Allergan, Inc. | DALVANCE (Drug) | Food and Beverage | In-kind items and services | $24.16 | General |
| Category: ANTI-INFECTIVE | ||||||
| 06/24/2020 | Insmed, Inc. | Arikayce (Drug) | Food and Beverage | In-kind items and services | $15.67 | General |
| Category: Respiratory | ||||||
| 03/11/2020 | Insmed, Inc. | Arikayce (Drug) | Food and Beverage | In-kind items and services | $18.33 | General |
| Category: Respiratory | ||||||
| 11/15/2019 | Relypsa, Inc. | Veltassa (Drug) | Food and Beverage | In-kind items and services | $23.15 | General |
| Category: Hyperkalemia | ||||||
| 11/06/2019 | Insmed, Inc. | Arikayce (Drug) | Food and Beverage | In-kind items and services | $104.62 | General |
| Category: Respiratory | ||||||
| 08/21/2019 | Sunovion Pharmaceuticals Inc. | APTIOM (Drug) | Food and Beverage | In-kind items and services | $14.46 | General |
| Category: CNS | ||||||
| 05/16/2019 | Scilex Pharmaceuticals Inc. | ZTLido 30 POUCH in 1 CARTON 1 PATCH in 1 POUCH (Drug) | Food and Beverage | In-kind items and services | $16.67 | General |
| Category: Analgesic | ||||||
| 02/14/2019 | Merck Sharp & Dohme Corporation | NOXAFIL (Drug), PREVYMIS, DIFICID | Food and Beverage | In-kind items and services | $17.82 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 01/24/2019 | TETRAPHASE PHARMACEUTICALS, INC. | Xerava (Drug) | Food and Beverage | In-kind items and services | $20.49 | General |
| Category: Complicated Intra-Abdominal Infections | ||||||
| 01/24/2019 | Vyera Pharmaceuticals, LLC | Daraprim 30 Tablet in 1 Bottle (Drug) | Food and Beverage | In-kind items and services | $16.71 | General |
| Category: Toxoplasmosis | ||||||
| 01/10/2019 | Merck Sharp & Dohme Corporation | NOXAFIL (Drug), PREVYMIS, DIFICID | Food and Beverage | In-kind items and services | $14.19 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 12/12/2018 | Astellas Pharma US Inc | — | Education | In-kind items and services | $69.99 | General |
| 12/07/2018 | Astellas Pharma US Inc | — | Education | In-kind items and services | $28.99 | General |
| 11/29/2018 | Astellas Pharma US Inc | CRESEMBA (Drug), AMBISOME, MYCAMINE | Food and Beverage | In-kind items and services | $21.43 | General |
| Category: INFECTIOUS DISEASES | ||||||
| 11/01/2018 | Allergan Inc. | AVYCAZ (Drug) | Food and Beverage | In-kind items and services | $14.26 | General |
| Category: ANTI-INFECTIVE | ||||||
| 09/26/2018 | Theratechnologies Inc. | EGRIFTA (Drug) | Food and Beverage | In-kind items and services | $23.20 | General |
| Category: HIV | ||||||
| 09/06/2018 | Theravance Biopharma, Inc. | VIBATIV (Drug) | Food and Beverage | In-kind items and services | $18.94 | General |
| Category: Infectious Disease | ||||||
| 08/23/2018 | Melinta Therapeutics, Inc. | Baxdela (Drug), Vabomere, Orbactiv | Food and Beverage | In-kind items and services | $23.88 | General |
| Category: INFECTIOUS DISEASES | ||||||
| 08/16/2018 | Merck Sharp & Dohme Corporation | CUBICIN RF (Drug), ZERBAXA | Food and Beverage | In-kind items and services | $13.51 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 07/26/2018 | ViiV Healthcare Company | JULUCA (Drug), TRIUMEQ | Food and Beverage | In-kind items and services | $17.82 | General |
| Category: HIV | ||||||
| 07/25/2018 | Merck Sharp & Dohme Corporation | NOXAFIL (Drug), PREVYMIS, DIFICID | Food and Beverage | In-kind items and services | $12.33 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 07/19/2018 | Merck Sharp & Dohme Corporation | NOXAFIL (Drug), PREVYMIS, DIFICID | Food and Beverage | In-kind items and services | $16.85 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 07/02/2018 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $22.05 | General |
| 02/23/2018 | Merck Sharp & Dohme Corporation | CUBICIN RF (Drug), ZERBAXA, SIVEXTRO | Food and Beverage | In-kind items and services | $15.00 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 02/15/2018 | Janssen Biotech, Inc. | PREZCOBIX (Drug) | Food and Beverage | In-kind items and services | $19.98 | General |
| Category: Infectious Diseases & Vaccines | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 528 | 1,661 | $461,195 | $124,839 |
| 2022 | 4 | 567 | 1,808 | $502,720 | $132,607 |
| 2021 | 15 | 1,115 | 3,171 | $639,887 | $226,803 |
| 2020 | 8 | 709 | 1,975 | $409,190 | $153,592 |
Total Patients
2,919
Total Services
8,615
Medicare Billing
$637,840
Procedure Codes
32
All Medicare Procedures & Services
32 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 232 | 1,199 | $299,750 | $73,538 | 24.5% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 205 | 244 | $100,040 | $32,384 | 32.4% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 61 | 171 | $51,300 | $15,726 | 30.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 30 | 47 | $10,105 | $3,190 | 31.6% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 220 | 1,243 | $310,750 | $69,089 | 22.2% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 223 | 263 | $107,830 | $40,390 | 37.5% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 71 | 226 | $67,800 | $18,087 | 26.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 53 | 76 | $16,340 | $5,041 | 30.9% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 329 | 1,832 | $336,260 | $104,470 | 31.1% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 317 | 380 | $155,800 | $59,989 | 38.5% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 124 | 361 | $76,440 | $29,642 | 38.8% |
| 99335 | Established patient assisted living visit, typically 25 minutes | Office | 2021 | 25 | 81 | $11,664 | $6,027 | 51.7% |
| 11721 | Removal of tissue from 6 or more finger or toe nails | Office | 2021 | 95 | 156 | $10,764 | $4,941 | 45.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 39 | 64 | $13,760 | $4,893 | 35.6% |
| 11042 | Removal of skin and tissue first 20 sq cm or less | Office | 2021 | 14 | 43 | $7,697 | $4,447 | 57.8% |
| 99334 | Established patient assisted living visit, typically 15 minutes | Office | 2021 | 27 | 56 | $5,096 | $2,580 | 50.6% |
| 99309 | Subsequent nursing facility visit, typically 25 minutes per day | Facility | 2021 | 17 | 33 | $4,587 | $2,390 | 52.1% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 14 | 15 | $4,140 | $1,622 | 39.2% |
| 11056 | Removal of 2 to 4 thickened skin growths | Office | 2021 | 16 | 25 | $3,750 | $1,330 | 35.5% |
| 99308 | Subsequent nursing facility visit, typically 15 minutes per day | Facility | 2021 | 19 | 24 | $2,520 | $1,318 | 52.3% |
| 99212 | Established patient outpatient visit, total time 10-19 minutes | Office | 2021 | 18 | 23 | $1,380 | $985.17 | 71.4% |
| 11721 | Removal of tissue from 6 or more finger or toe nails | Facility | 2021 | 35 | 49 | $3,381 | $873.45 | 25.8% |
| 11055 | Removal of single thickened skin growth | Office | 2021 | 15 | 18 | $954.00 | $706.84 | 74.1% |
| 99202 | New patient outpatient visit, total time 15-29 minutes | Office | 2021 | 11 | 11 | $1,694 | $587.70 | 34.7% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 247 | 1,270 | $203,200 | $73,728 | 36.3% |
About Dr. Rodrigo Romulo, MD
Dr. Rodrigo Romulo, MD is a Infectious Disease healthcare provider based in Chesapeake, Virginia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/15/2006. The National Provider Identifier (NPI) number assigned to this provider is 1467565614.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Rodrigo Romulo, MD has received a total of $1,071 in payments from pharmaceutical and medical device companies, with $58.16 received in 2020. These payments were reported across 48 transactions from 17 companies. The most common payment nature is "Food and Beverage" ($971.67).
As a Medicare-enrolled provider, Romulo has provided services to 2,919 Medicare beneficiaries, totaling 8,615 services with total Medicare billing of $637,840. Data is available for 4 years (2020–2023), covering 32 distinct procedure/service records.
Ad
Practice Information
- Specialty Infectious Disease
- Location Chesapeake, VA
- Active Since 08/15/2006
- Last Updated 10/28/2014
- Taxonomy Code 207RI0200X
- Entity Type Individual
- NPI Number 1467565614
Products in Payments
- Arikayce (Drug) $138.62
- VIBATIV (Drug) $104.38
- NOXAFIL (Drug) $97.16
- Myrbetriq (Drug) $73.83
- TRIUMEQ (Drug) $67.18
- JULUCA (Drug) $62.40
- CUBICIN RF (Drug) $46.07
- EGRIFTA (Drug) $38.14
- PREZCOBIX (Drug) $34.96
- SUSTIVA (Drug) $32.98
- DALVANCE (Drug) $24.16
- Baxdela (Drug) $23.88
- Veltassa (Drug) $23.15
- CRESEMBA (Drug) $21.43
- Xerava (Drug) $20.49
- Daraprim 30 Tablet in 1 Bottle (Drug) $16.71
- ZTLido 30 POUCH in 1 CARTON 1 PATCH in 1 POUCH (Drug) $16.67
- APTIOM (Drug) $14.46
- AVYCAZ (Drug) $14.26
- ISENTRESS (Drug) $13.12
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.